Aspira Pathlab & Diagnostics Ltd
BSE: 540788
values in crores
Revenue & Profit Trend
in croresRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|---|
| INCOME | |||||||
| Revenue | 6.52+27.4% | 5.12-36.7% | 8.09+54.2% | 5.25-9.2% | 5.78+6.8% | 5.41-12.5% | 6.18 |
| Other Income | 0.14+7.5% | 0.13-7.2% | 0.14+29.5% | 0.11-17.4% | 0.13+46.5% | 0.09+17.1% | 0.08 |
| Total Income | 6.66+26.9% | 5.25-36.2% | 8.23+53.7% | 5.36-9.3% | 5.91+7.5% | 5.50-12.1% | 6.25 |
| EXPENSES | |||||||
| Expenditure | 7.35+7.9% | 6.81+6.4% | 6.40+30.9% | 4.89-5.7% | 5.18+1.3% | 5.12-2.7% | 5.26 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| PROFIT | |||||||
| PBT | -0.69+55.9% | -1.56-185.1% | 1.84+291.0% | 0.47-35.1% | 0.72+91.9% | 0.38-61.9% | 0.99 |
| Net Profit | -0.69+55.9% | -1.56-185.1% | 1.84+291.0% | 0.47-35.1% | 0.72+91.9% | 0.38-61.9% | 0.99 |
| KEY METRICS | |||||||
| OPM % | -5.11%+18.53pp | -23.64%-50.69pp | 27.05%+11.41pp | 15.64%-2.60pp | 18.24%+21.79pp | -3.55%-11.17pp | 7.62% |
| NPM % | -10.34%+19.41pp | -29.75%-52.05pp | 22.30%+13.54pp | 8.76%-3.48pp | 12.24%+5.38pp | 6.86%-8.97pp | 15.83% |
| EPS | 0.67-55.9% | 1.52-14.6% | 1.78+287.0% | 0.46-34.3% | 0.70+89.2% | 0.37-61.5% | 0.96 |
Corporate Events
Board MeetingASPIRA
202623May
Board Meeting
The board meeting is scheduled to consider and approve the a…
BSE Filing ↗ Board MeetingASPIRA
202610Feb
Board Meeting
consider and approve Unaudited Standalone Financial Results,…
BSE Filing ↗ Board MeetingASPIRA
202516May
Board Meeting
Consider and approve Audited Standalone Financial Results al…
BSE Filing ↗ Board MeetingASPIRA
20257Feb
Board Meeting
Consider and approve Unaudited Standalone Financial Results …
BSE Filing ↗ Board MeetingASPIRA
202412Nov
Board Meeting
Consider and approve Unaudited Standalone and Consolidated F…
BSE Filing ↗ Board MeetingASPIRA
202428May
Board Meeting
consider and approve Audited Financial Results (Standalone) …
BSE Filing ↗